Delving into the Latest Updates on AWD.pharma GmbH & Co. KG with Synapse

概览

关联

3

项与 AWD.pharma GmbH & Co. KG 相关的临床试验

EUCTR2009-013268-38-DE

/ Not yet recruitingN/A

A multicentre, double-blind, randomised, active- and placebo-controlled clinical trial on the pain relieving effects of the modfied-release formulation of flupirtine in patients suffering from moderate to severe chronic low back pain

开始日期2009-09-29

申办/合作机构

AWD.pharma GmbH & Co. KG

NCT01676246

/ Completed临床1期IIT

Pharmacokinetics, Metabolism and Analgesic Effects of Flupirtine After Intravenous, Single Dose and Chronic Oral Administration in Healthy Subjects Genotyped for NAT2, UGT1A1 and GSTP1

Flupirtine is metabolized in-vitro via carbamate cleavage and N acetylation to glucuronides and mercapturic acid derivatives. The formation of reactive, toxic intermediate products may be influenced by genetic polymorphisms of the involved conjugative metabolic pathways. So the purpose of this study is to measure pharmacokinetics, metabolism and analgesic effects of flupirtine in dependence on the function of NAT2, UGT1A1 and GSTP1.

开始日期2008-05-01

申办/合作机构

University of Greifswald

[+1]

EUCTR2005-002959-41-DE

/ Not yet recruitingN/A

A multicentre, double-blind, randomised, placebo-controlled clinical trial to investigate pain relieving effects of the modified release (MR) formulation of flupirtine in patients suffering from moderate to severe chronic low back pain.

开始日期2005-10-10

申办/合作机构

AWD.pharma GmbH & Co. KG

100 项与 AWD.pharma GmbH & Co. KG 相关的临床结果

登录后查看更多信息

0 项与 AWD.pharma GmbH & Co. KG 相关的专利（医药）

登录后查看更多信息

13

项与 AWD.pharma GmbH & Co. KG 相关的文献（医药）

2008-11-01·MMW Fortschritte der Medizin

AT1-Antagonist bewährt sich auch im Praxisalltag

Article